Background
Gilead Sciences develops and sells prescription medications, including the HIV drug Biktarvy. After a Maryland patient received Turkish-market Biktarvy through his employer’s self-funded health plan, Gilead investigated and found that hundreds of bottles of foreign-market Gilead medications had been shipped to patients in the United States. Although the imported drugs were manufactured with Gilead’s authorization and chemically identical to their U.S. counterparts, their foreign-language labels and accompanying materials omitted warnings, identifying information, and other disclosures included with the domestic products.
Gilead sued Rx Valet, Advanced Pharmacy, Affordable Rx, and executive Gregory Santulli—the “Quartet”—for direct trademark infringement. It alleged that Meritain Health, the plan’s third-party administrator, and ProAct, its pharmacy benefit manager, contributorily infringed by providing patient data, claim-processing services, system edits, and other assistance that facilitated the importation program. The District of Maryland preliminarily enjoined the defendants from importing, advertising, selling, or facilitating the sale of imported Gilead-branded medications.
The Court’s Holding
The Fourth Circuit affirmed. Adopting the material-differences doctrine for gray-market goods, the court held that Gilead was likely to prove the imported medications were not genuine for Lanham Act purposes. Their foreign-language labeling, omitted warnings and regulatory information, lack of National Drug Code numbers, and other differences cleared the doctrine’s low materiality threshold. The drugs also bypassed Gilead’s domestic temperature monitoring, chain-of-custody, recall, and authorized-distribution controls. Chemical identity did not eliminate those material and quality-control differences, and the first-sale doctrine therefore did not defeat Gilead’s claims.
The court also held that Gilead was likely to establish contributory infringement by Meritain and ProAct. Under the governing Inwood standard, prior specific notice from a trademark owner is not required if a service provider knows or has reason to know that identified parties are infringing and continues supplying services. The record supported findings that both companies knew or should have known they were facilitating the importation of materially different Gilead medications. The Fourth Circuit declined to add “degree of control” as a separate element of contributory trademark infringement.
The Federal Food, Drug, and Cosmetic Act did not preclude the Lanham Act claims because adjudicating material differences did not require interpreting or enforcing FDA regulations. The court also upheld the findings on irreparable harm, the equities, and the public interest. Gilead’s ten-month pre-suit investigation did not rebut the statutory presumption of irreparable harm, and the district court did not abuse its discretion in entering preliminary relief.
Key Takeaways
- Foreign-market goods bearing authentic trademarks may still be non-genuine under the Lanham Act when they materially differ from authorized domestic goods or bypass the trademark owner’s legitimate quality controls.
- For prescription drugs, differences in language, warnings, regulatory disclosures, traceability, transportation monitoring, and recall coverage may be material even when the drugs are chemically identical.
- Contributory infringement does not require prior notice from the trademark owner or a separate showing of control when a defendant continues supplying services to identified infringers it knows or has reason to know are infringing.
Why It Matters
The published decision brings the Fourth Circuit into line with other circuits recognizing the material-differences doctrine for gray-market goods and applies that doctrine to imported prescription drugs. It confirms that trademark genuineness encompasses labeling, safety information, distribution safeguards, and quality controls—not merely a product’s composition or authenticity at manufacture.
The ruling also clarifies the exposure of health-plan administrators, pharmacy benefit managers, and other service providers that knowingly facilitate international drug-sourcing programs. A provider cannot necessarily avoid contributory liability merely because the trademark owner did not first send a cease-and-desist letter or because another participant physically imported and dispensed the products.